Amedeo Smart

Free Medical Literature Service

 

Amedeo

HIV Infection
  Free Subscription

Articles published in
Vaccine
    December 2025
  1. HAMMOUD M, Smith AKJ, Sachs O, Bavinton BR, et al
    Drivers, barriers, and implications of mpox vaccine uptake in Australia among gay, bisexual, and other men who have sex with men: results from a prospective observational mixed-methods study (2022-2024).
    Vaccine. 2025;70:128041.
    >> Share

    November 2025
  2. LE TOURNEAU N, Sharma A, Pry JM, Haambokoma M, et al
    Drivers of decision-making for future adult vaccines: a best-worst scaling among community members and health care workers in Zambia.
    Vaccine. 2025;70:128003.
    >> Share

  3. FREY SE, Baden LR, El Sahly HM, Davey RT, et al
    Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination.
    Vaccine. 2025;69:127959.
    >> Share

  4. CHAVES SS, Castells VB, Wague S, Tian Z, et al
    Chlamydia vaccine willingness among young adults in Australia.
    Vaccine. 2025;70:128027.
    >> Share

  5. RANA MM, Haydel B, Carrara G, Gleason C, et al
    Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.
    Vaccine. 2025;69:127969.
    >> Share

    October 2025
  6. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Corrigendum to "Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort" [Vaccine 62 (2025) 127580].
    Vaccine. 2025;67:127855.
    >> Share

  7. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
    Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
    Vaccine. 2025;66:127843.
    >> Share

  8. IVERSEN EF, Rahimic AHF, Frattari GS, Rosas-Umbert M, et al
    TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.
    Vaccine. 2025;66:127851.
    >> Share

  9. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
    Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
    Vaccine. 2025;66:127825.
    >> Share

  10. CLAY PA, Markowitz LE, Gopalani SV, Baxter A, et al
    HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving.
    Vaccine. 2025;65:127798.
    >> Share

  11. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
    Corrigendum to "Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa" [Vaccine 64 (2025) 127770].
    Vaccine. 2025;65:127797.
    >> Share

    September 2025
  12. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
    Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa.
    Vaccine. 2025;64:127770.
    >> Share

  13. ARSUFFI S, Rossi L, Colombo FR, Inverardi M, et al
    Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine.
    Vaccine. 2025;64:127723.
    >> Share

  14. BOGA DJ, Robinson M, Tirupathi M, Juste RS, et al
    Latent class and time-to-event analyses of social determinants of health and COVID-19 vaccine uptake among Black women living with HIV.
    Vaccine. 2025;64:127649.
    >> Share

    August 2025
  15. BARLOW M, Flanagan S, Ghosh I, Carter J, et al
    Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
    Vaccine. 2025;63:127639.
    >> Share

  16. YOU D, Quan J, Bishai D, Lam WWT, et al
    Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong.
    Vaccine. 2025;63:127625.
    >> Share

  17. YAMEY G, Beyrer C
    The dismantling of the U.S. vaccine regulatory framework.
    Vaccine. 2025;62:127557.
    >> Share

  18. GAO L, Zhang X, Mo X, Sun Y, et al
    Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.
    Vaccine. 2025;62:127596.
    >> Share

  19. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.
    Vaccine. 2025;62:127580.
    >> Share

    July 2025
  20. EXCLER JL, Saluja T, Wilder-Smith A, Kaminski RW, et al
    Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.
    Vaccine. 2025;62:127515.
    >> Share

  21. CARDENAS-GARZON K, Agudelo MC, Tovar-Aguirre OL, Reuter C, et al
    Understanding the decline in HPV vaccination in Colombia: A population-based analysis of girls and parents in early rollout cohorts.
    Vaccine. 2025;62:127507.
    >> Share

  22. MURATA M, Matsumoto Y, Shimono N
    Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1.
    Vaccine. 2025;62:127457.
    >> Share

  23. GIULIANO AR, Beltrame A, Villa LL, Lazcano-Ponce E, et al
    Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial
    Vaccine. 2025;61:127447.
    >> Share

  24. FREITAS C, Cooper CL, Kroch AE, Moineddin R, et al
    COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, Canada.
    Vaccine. 2025;61:127422.
    >> Share

    June 2025
  25. JOLFAYI AG, Alipour S, Aminizadeh S, Yaghoubi SM, et al
    Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.
    Vaccine. 2025;61:127340.
    >> Share

    May 2025
  26. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    >> Share

  27. MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
    Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
    Vaccine. 2025;57:127133.
    >> Share

    April 2025
  28. MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
    2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
    Vaccine. 2025;56:127120.
    >> Share

  29. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    >> Share

  30. STRONG C, Joson P, Chu IY, Chuang TT, et al
    Prioritization and barriers of mpox vaccination uptake among gay, bisexual and other men who have sex with men in Taiwan: 2023 HEART survey.
    Vaccine. 2025;53:127059.
    >> Share

    March 2025
  31. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    >> Share

  32. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    >> Share

  33. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    >> Share

  34. EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al
    Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.
    Vaccine. 2025;55:127008.
    >> Share

  35. MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al
    Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024.
    Vaccine. 2025;55:127014.
    >> Share

  36. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    >> Share

    February 2025
  37. COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
    Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
    Vaccine. 2025;49:126778.
    >> Share

  38. SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
    Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
    Vaccine. 2025;50:126846.
    >> Share

  39. MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
    Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
    Vaccine. 2025;50:126818.
    >> Share

  40. JENNINGS MC, Nabia S, Morgan C, Nduka CC, et al
    Realist review of low- to upper-middle-income country experiences on integration of HPV vaccination with other adolescent health services.
    Vaccine. 2025;50:126833.
    >> Share

    January 2025
  41. GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
    Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
    Vaccine. 2025;49:126777.
    >> Share

  42. KAUL R, Leidner AJ, Chesson HW
    Trends in costs of routinely recommended vaccines in the United States, 2001-2023.
    Vaccine. 2025;47:126667.
    >> Share

    December 2024
  43. PEREZ-SAUCEDO D, Castro-Perea NV, Ruiz-Cruz A, Bustos-Jaimes I, et al
    Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
    Vaccine. 2024;45:126663.
    >> Share

  44. KASSAM P, El-Zein M, Tota JE, Tellier PP, et al
    HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.
    Vaccine. 2024;45:126644.
    >> Share

  45. SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
    Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
    Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
    >> Share

    October 2024
  46. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    >> Share

  47. TRAVILL DI, Machalek DA, Rees H, Mbulawa Z, et al
    High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV.
    Vaccine. 2024;42:126442.
    >> Share

  48. EARP M, Meng L, Black CL, Carter RJ, et al
    Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
    Vaccine. 2024;42:126372.
    >> Share

    September 2024
  49. WITTESAELE C, Toska E, Cluver L, Weiss HA, et al
    Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the eastern cape, South Africa.
    Vaccine. 2024;42:126318.
    >> Share

  50. KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
    Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
    Vaccine. 2024;42:126320.
    >> Share

    August 2024
  51. NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
    How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
    Vaccine. 2024;42:126215.
    >> Share

  52. GUZMAN RUIZ L, Zollner AM, Hoxie I, Kuchler J, et al
    Enhancing NA immunogenicity through novel VLP designs.
    Vaccine. 2024;42:126270.
    >> Share

  53. GEORGE G, Strauss M, Lansdell E, Nota P, et al
    Factors associated with COVID-19 vaccine uptake among south African health care workers.
    Vaccine. 2024;42:126181.
    >> Share

    July 2024
  54. JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al
    Vaccine value profile for herpes simplex virus.
    Vaccine. 2024;42.
    >> Share

  55. MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al
    Vaccine value profile for invasive non-typhoidal Salmonella disease.
    Vaccine. 2024;42.
    >> Share

  56. HU TH, Tou CY, Lee YH, Chang HH, et al
    Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan.
    Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024.
    >> Share

    June 2024
  57. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    >> Share

    May 2024
  58. NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
    The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
    Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  59. BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
    Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
    Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  60. YEGANEH N, Yin S, Moir O, Danza P, et al
    Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.
    Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  61. CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al
    Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
    Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  62. GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al
    Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.).
    Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  63. KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al
    Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region.
    Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024.
    >> Share

    April 2024
  64. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  65. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  66. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    >> Share

    March 2024
  67. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  68. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  69. BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
    A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
    Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
    >> Share

    February 2024
  70. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  71. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    >> Share

    December 2023
  72. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016